Effects of tofacitinib vs methotrexate on clinical and molecular disease activity in joints and lungs in early rheumatoid arthritis (the PULMORA study)
Pulmonary abnormalities are prevalent in patients with early rheumatoid arthritis (RA) but often undetected and neglected in clinical praxis. Up to 10% of RA patients will develop interstitial lung disease (ILD) with high mortality. Identification of these patients is hampered by a lack of specific symptoms and diagnostic tools. No specific treatment is available and some anti-rheumatic drugs have even been suggested to contribute to ILD. Recent data indicate that novel Janus kinase inhibitors (JAKi) on the contrary could be beneficial.
The aim of the PULMORA study is to determine whether the JAKi tofacitinib, registered for RA, is an effective and safe treatment for patients with interstitial pulmonary findings on High resolution computed tomography (HRCT) at diagnosis.